Last updated: 13 June 2024 at 4:26pm EST

Clare Kahn Net Worth




The estimated Net Worth of Clare Kahn is at least $8.24 Thousand dollars as of 7 June 2024. Clare Kahn owns over 1,100 units of Solid Biosciences Inc stock worth over $8,239 and over the last 4 years Clare sold SLDB stock worth over $0.

Clare Kahn SLDB stock SEC Form 4 insiders trading

Clare has made over 1 trades of the Solid Biosciences Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Clare bought 1,100 units of SLDB stock worth $8,437 on 7 June 2024.

The largest trade Clare's ever made was buying 1,100 units of Solid Biosciences Inc stock on 7 June 2024 worth over $8,437. On average, Clare trades about 183 units every 0 days since 2021. As of 7 June 2024 Clare still owns at least 1,100 units of Solid Biosciences Inc stock.

You can see the complete history of Clare Kahn stock trades at the bottom of the page.



What's Clare Kahn's mailing address?

Clare's mailing address filed with the SEC is C/O SOLID BIOSCIENCES INC., 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN, MA, 02129.

Insiders trading at Solid Biosciences Inc

Over the last 7 years, insiders at Solid Biosciences Inc have traded over $9,620,465 worth of Solid Biosciences Inc stock and bought 13,973,934 units worth $97,227,521 . The most active insiders traders include Advisors Llcperceptive Life..., Capital Management, L.P.Ra ..., and Rajeev M. Shah. On average, Solid Biosciences Inc executives and independent directors trade stock every 38 days with the average trade being worth of $1,822,871. The most recent stock trade was executed by Ian F Smith on 3 July 2024, trading 3,255 units of SLDB stock currently worth $24,380.



What does Solid Biosciences Inc do?

solid biosciences (solid) is a cambridge, ma based biotech company singularly focused on developing treatments and cures for duchenne muscular dystrophy (dmd). solid combines sharp commercial focus with world-class science to advance promising therapies and is positioned to catalyze therapeutic development across all aspects of the disease. condition-focused, our mandate is comprehensive; improving daily life for patients and attacking the roots of dmd.



What does Solid Biosciences Inc's logo look like?

Solid Biosciences Inc logo

Complete history of Clare Kahn stock trades at Solid Biosciences Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
7 Jun 2024 Clare Kahn
Buy 1,100 $7.67 $8,437
7 Jun 2024
1,100


Solid Biosciences Inc executives and stock owners

Solid Biosciences Inc executives and other stock owners filed with the SEC include: